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Purpose of review: the present review focuses on the new therapeutic opportunities offered by the 
combination of biological drugs, mainly Rituximab, with Direct-acting Antiviral Agents (DAAs). 
Recent findings: hepatitis C virus (HCV) is known to be the etiologic agent in the majority of patients 
with mixed cryoglobulinemia syndrome (MC). Clinical research has been focused on anti-viral drugs 
and, more recently, on the new, highly potent DAAs. New DAAs assure sustained virologic response 
(SVR) rates >90% with relief of mild to moderate symptoms. 
Summary: MC may present with multi-organ vasculitis involving kidneys, joints, skin, and peripheral 
nerves. Data on DAAs efficacy in HCV-associated cryoglobulinemic vasculitis (CV) are disappointing 
possibly due to the inability of these drugs to suppress the immune-mediated process once it has been 
triggered. Immunosuppression has often been employed in the past as a first-line therapy in CV despite 
the potential risk of the infection exacerbation. However, more manageable Rituximab-based 
therapeutic approaches have been more recently used without increase of viral load. Rituximab 
substantially changed the outcome of HCV-associated cryoglobulinemic vasculitis by providing long-
term remission. A combination schedule of DAAs and Rituximab may result in eradication of both CV 
and HCV infection.   
 











Abbreviations: Hepatitis C Virus (HCV), cryoglobulinemia syndrome (CM), cryoglobulinemic vasculitis 
(CV), immune complexes (ICs), pegylated-interferon-α (peg-IFNα), ribavirin (RBV), nonstructural (NS), 
direct-acting antiviral agents (DAAs). 
 
Introduction 
Mixed cryoglobulinemia syndrome is characterised by the appearance in the circulation of mixed 
cryoglobulins, a particular type of immune complexes (ICs) that may deposit in several tissues. Several 
conditions can be found to be associated with MC, but most of them are related to a  HCV infection [1-
6]. While circulating cryoglobulins may be detected in about 40% of infected patients  and are usually 
asymptomatic, a CV occurs in a minority of cases (<2%) [7] with long-term HCV infection and older age 
[8,9].  
Purpose of the present review is to provide data on the therapeutic opportunities of CV offered by the 
DAAs and biological drugs, mainly Rituximab. 
 
Pathogenic aspects relevant to therapy  
HCV infects not only hepatocytes, but also B-lymphocytes, macrophages,  peripheral dendritic cells and 
monocytes [10]. More specifically,  HCV-RNA,  HCV-NS3 and core proteins have been restrictively found 
in CD19-positive B-cells [11], which incidentally are the target cells for Rituximab-based regimens. HCV 
stimulation enhances the expression of lymphomagenesis-related genes [12]. Under this trigger effect, 
permanent clones of B-lymphocytes produce oligo- or monoclonal IgM that are known to display 
rheumatoid factor activity,  favouring the formation of ICs formed by the monoclonal IgM itself, HCV, 
and anti-HCV polyclonal IgG antibodies. Due to the presence of IgM, these ICs escape the splenic and 
hepatic macrophage removal system [13], and, when phagocytosed, are not degraded by monocytes as 
shown both in humans [14] and in murine models [15]. The release of pro-inflammatory cytokines and 
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pro-cathepsin D from activated macrophages perpetuates tissue damage [15]. Based on these 
pathogenic principles it seems unlikely that antiviral agents can effectively interfere with the 
pathogenesis of MC vasculitis once the immune process is definitively triggered, and impact the 
immune-mediated injury. 
 
Rituximab as a target therapeutic approach for CV 
Rituximab is a monoclonal antibody directed at the lymphocyte membrane protein CD20. Rituximab 
selectively depletes the CD20/CD19+veB lymphocytes, thereby abolishing IgM production and new 
cryoglobulin formation. It is noteworthy that HCV proteins and RNA have been restrictively detected in 
these cells [11].  
Several hundred of Rituximab-treated patients have been reported in the literature [16–37]. This agent 
has been proven to be effective in the management of skin ulcers, renal manifestations in 75–90% of 
case, and sensitive-motor neuropathy in 70%. Rituximab depletes bone marrow B-cell clonal expansion 
resulting in a decrease of serum cryoglobulins and rheumatoid factor with normalisation of C4 levels 
[35–39].  
We prospectively evaluated the very long-term effects (mean follow-up 72.47 months) of Rituximab in 
patients with severe CV [35]. Rituximab was given to 31 patients (27 HCV+ve) with MC (type II in 29 
subjects and type III in 2) and diffuse membranoproliferative glomerulonephritis (16 cases), sensitive-
motor neuropathy (26 cases) and severe skin ulcers (7 cases). Rituximab was given at a dose of 375 
mg/m2 (days 1, 8, 15 and 22, followed by 2 more doses 1 and 2 months later, the so-called “4 plus 2 
protocol”). Five patients also received 3 pulses of 500 mg of methylprednisolone. No other 
immunosuppressive or antiviral drugs were added. A complete remission of pre-treatment active 
manifestations in all cases of purpuric lesions and non-healing vasculitic ulcers (Figure 1), and in 80% 
of the peripheral neuropathies was achieved. Re-induction with Rituximab was given in 9 relapsing 
patients after a mean of 31.1 months, resulting again effective. After 6 years of follow-up, the survival 
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rate was 75% and the probability of remaining symptom-free for 10 years without any therapy was 
60% after a single “4 plus 2” cycle, while the likelihood of living symptom-free for 5 years after relapse 
was 80% if treated with the same protocol. Viral load did not increase in HCV+ve patients.  This open 
study showed Rituximab to be safe and effective for treating the most severe cases of MC, even in a very 
long-term perspective (6 years).  
16 open-label trials with at least 10 patients with 440 patients could be recruited [16-31]. Median 
complete remission (CR) was 68%, partial remission (PR) was 14%, and no response was 10%.  
Focusing on case series reporting renal outcomes [16-18, 21, 23-27, 30, 31], 143 patients could be 
identified, but only a minority had biopsy-proven evidence of cryoglobulinemic glomerulonephritis. 
Median rates of renal complete and partial remission were 57% and 20%, respectively. 
Among the three RCTs [32-34], in 2010 Dammacco and co-workers [32] investigated the safety and 
efficacy of a combined use of pegylated-interferon-α (peg-IFNα) and ribavirin (RBV), with or without 
Rituximab, in HCV–related MC. Twenty-two patients with HCV-related MC received peg-IFNα weekly 
plus RBV for 48 weeks plus Rituximab 375 mg/m2 once a week for 1 month followed by two 5-monthly 
infusion. Fifteen additional patients received peg-IFNαI and RBV with the same modalities, but without 
Rituximab. In Rituximab group CR was achieved in 54.5% (versus 33.3% of the control group, p< 0.05),   
In a prospective multi-center RCT investigating Rituximab in severe CV, 59 patients were randomized 
to receive a conventional treatment (consisting of one of the following 3 options: glucocorticoids; 
azathioprine or cyclophosphamide; plasmapheresis) or Rituximab (2 infusions of 1 g each)[34]. 
Rituximab resulted to be the best therapy for all 3 target-organ manifestations (skin ulcers, active 
glomerulonephritis, or refractory peripheral neuropathy). The number of patients who achieved the 
primary endpoint was statistically higher in the Rituximab group both at 1and 2 years (p<0.0001). 
In a single-center, open label, RCT, Rituximab was compared to the best available therapy in patients 
affected by HCV-associated CV. Six months after the beginning of the treatment 10 out of 12 patients in 
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the Rituximab group (83%) and 1 of 12 patients in the control group (8%) were in remission (p< 0.001) 
[33].  No effects of Rituximab on HCV viremia was observed.  
Notably, by examining results from 11 studies using Rituximab (administered either in 4 weekly 
infusions or as 1 g given 15 days apart) in which renal outcome was addressed,  the median CR rate of 
57%. In a large cohort of renal patients given the 4+2 regimen CR was achieved in 75% of cases. The “4 
plus 2 protocol might intensify the depleting effect of Rituximab on lymphocytes when compared to 
other Rituximab regimens (i.e., “Lymphoma” and “Rheumatoid Arthritis” protocols), thus maintaining a 
more prolonged B-cell depletion and improving clinical outcome.  
MC is an immune-mediated process that becomes independent from the triggering virus. Rituximab is 
much more selective than conventional immunosuppressive treatments at interfering with the 
downstream processes following the disease trigger [35-36],  and is definitely safer, as shown in Figure 
2. No increase in viraemia could be detected possibly due to Rituximab depleting effects of the CD19+ve 
cells which serve as reservoir for HCV. Rituximab specifically targets the nephrotoxic Ig-producing cells 
inducing a lymphocyte subpopulation re-assessment (Figure 3). 
 
The potential role of direct antiviral agents  
Before the advent of direct-acting antiviral agents (DAAs), chronic HCV infection was mainly treated 
with peg-IFN and RBV [37] which achieved eradication of infection in fewer than 50% of naıve patients 
with genotype 1 infection [38,39].  
With regard to HCV-associated CV, PegIFN/RBV therapy was found to be consistently effective only 
when given with Rituximab either in a combined [32] or sequential [21] scheme.  
The new DAAs showed significant antiviral efficacy (>90% cure) and a good tolerance profile. The new 
drugs target the 3 nonstructural proteins: NS5A and NS5B RNA polymerase, the NS3 serine protease 
and its cofactor, NS4A. Daclatasvir was the first NS5A inhibitor to be launched, [42], followed by 
ledipasvir[43] and ombitasvir[37]. Overall, these DAAs are effective against a wide spectrum of HCV 
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genotypes  [41].   To date, sofosbuvir is the most advanced DAAs. Initially approved to be used in 
association with RBV for HCV infection (genotypes 2 and 3), it was the first all-oral, PegIFN-free 
regimen. Multidrug regimens are combinations of an NS3/4A inhibitor, an NS5A inhibitor and a non-
nucleoside NS5A inhibitor [44-46]. A full 3D treatment regimen achieves an SVR rate of >95% when 
administered for 12 weeks to naıve patients, and >90% in prior non-responders.   
DAAs could be expected to modify the incidence of vasculitis being the result of a prolonged history of 
HCV infection. However, these agents do not possess the immunomodulatory effects of the interferons. 
They likely do not interfere with the pathogenesis of MC vasculitis nor effectively impact on the 
development of the immune-mediated injury once the immune disorder is established. Besides, the 
uncertainty of their pharmacokinetics and safety in the case of renal impairment implies caution in 
nephritic patients. 
Results of the DAAs regimens in patients with HCV-related CV are difficult to interpret. Makara [40] 
reported remission of multiorgan involvement and withdrawal of serum cryoglobulins 4 weeks after 
initiating DAA-therapy  in a severe case of HCV-associated CV.  But this patient also had received 1,600 
mg of Rituximab in four doses 5 months earlier. Sise at al. [47] showed that patients with CV had 
sustained virological response rate at 12 weeks of 83% (10 out of 12 patients) with a sofosbuvir-based 
DAA regimen. Patients with glomerulonephritis (7 out of 12) showed a reduction in proteinuria and 
eGFR improvement. But only2 patients had a substantial amelioration of serum creatinine (one 
concomitantly treated with Rituximab and one whose renal involvement was not documented by renal 
biopsy). Functional changes were negligible in 4 patients, while serum creatinine increased over time 
in the remaining patient. As regard to the urinary abnormalities, the only patient who had nephrotic 
range proteinuria at baseline (dropped to non-nephrotic values) received Rituximab together with 
DAAs. Another patient who showed a moderate reduction of proteinuria (from 1,574 to 800 mg/g sCr) 
was concomitantly treated with ustekinumab, ananti-IL-12-23 monoclonal antibody, whose effects in 
proteinuric patients is presently unpredictable. Proteinuria decreased from 2,141 to 400 mg/g sCr in a 
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patient who had not undergone biopsy. Of the remaining 4 patients, proteinuria was negative in one 
case, not determined in another, and only determined by urinalysis in 2 cases. 
Sollima et al [41] treated 7 patients with HCV-associated CV with new DAAs within an expanded access 
program. Nephropathy was the most frequent manifestation, presenting as a severe nephrotic 
syndrome, stages III-IV chronic kidney disease or both. Patients were treated with a variety of DAA 
regimens, including ombitasvir/paritaprevir/ritonavir and dasabuvir, sofosbuvir plus ribavirin, 
sofosbuvir plus daclatasvir and sofosbuvir plus simeprevir, depending on HCV genotypes. Treatment 
was given for 12 weeks in five cases and 24 weeks in two. All patients achieved SVR at post-treatment 
week 12 (confirmed at week 24 in five of them, on a longer follow-up). Serum cryoglobulins were 
undetectable in 4 patients at the end of treatment but increasedagain in three during follow-up. At post-
treatment week 12, clinical response was observedonly in 2 patients. Specifically, theresponse was 
partial in one patient and complete in another who experienced vasculitis relapse despite still 
undetectable HCV RNA. Cornella and coworkers [48] reported  5 patients with genotype 1 chronic HCV-
related hepatitis complicated by MC who received 24 weeks triple therapy with bocepriviror, telaprivir 
and sofosbuvir. Clearance of serum cryoglobulins was not achieved in any of these patients.  
Lauletta et al. [49] described 22 patients with HCV-associated CV treated with new DAAs. Despite 
a sustained virological response in 63.7%, only partial benefits were observed in patients with 
peripheral neuropathy. The Authors inferred that the pathogenic process underlying CV might 
have progressed despite viral clearance and that a “point of no return” might have been 
overstepped. In a prospective study on HCV pts with symptomatic or asymptomatic 
cryoglobulinemia receiving DAAs, 71% of patients with vasculitis achieved a complete clinical 
response, including all 7 patients with kidney involvement. Since vasculitis relapsed in some 
patients, the authors speculated that incomplete suppression of the B-cell clonal proliferation 
might underlie the risk of virus-independent relapses [50].  
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Emery et al., [51] retrospectively evaluated 18 HCV-CV before and after treatment with DAA + 
pegINF. High sustained virological response (16/18) did not directly translate into improved 
immunological outcomes (with only 29.4% of patients having complete cryoprecipitate 
clearance).  Among the 7 patients with severe CV included in the study, only one had a complete 
clinical response, 3 showed a partial clinical response and 2 no improvement. The Authors 
concluded that patients with life-threatening vasculitis were not susceptible of immunological and 
clinical response. In a prospective international multicenter cohort study on 148 patients with 
symptomatic HCV- CV receiving DAAs followed-up for 15.3 months, DAAs therapy achieved high 
virological responses in most patients, with some immunological and clinical benefits but only 
partial hematological changes (and detectable cryoglobulins in half of the patients) [52]. Factors 




DAAs therapy in HCV-associated CV was found to achieve high virological responses with some  
immunological, clinical and hematological changes. However, these observations emphasised the 
role of DAAs in eradicating HCV infection even in MC patients, a subset that had been found less 
responsive to conventional antiviral treatment with Peg-IFN/RBV.  
General drawbacks of these studies included the lack of histological evidence of renal involvement 
in the vast majority of cases, what made uncertain the nature of the functional impairment or the 
urinary abnormalities in patients with co-morbidities potentially responsible for the renal 
manifestations. Moreover,  Del Padre et al. (53) observed that the clonal B cell could persist after 
the withdrawal of HCV, but underwent functional changes that might decrease their capacity to 
secrete pathogenic antibody. Events able to perturb immunologic homeostasis could reactivate 
these cells and lead to the resurgence of CV. Finally, virus eradication does not necessarily mean 
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that the immunological process has been stopped and several patients continue to have B 
lymphocyte clonal expansion after SVR.  
A complete remission of MC associated with sustained virological response following a combined 
regimen of Peg-IFN+RBV+DAA plus Rituximab was described by Urraro et al [42]. A combination 
of DAAs and Rituximab can be effective both in CV treatment and in HCV eradication.  Rituximab, 
able to deplete CD19 positive-B cells, known to be HCV reservoirs, could contribute to viral 
eradication making its combination with DAAs particularly attractive in the treatment of HCV-
related CV. However, the optimal combination protocol of Rituximab plus DAAs need to be defined 
(54).  Severe CV, especially with renal involvement, should first be treated with a Rituximab-based 
protocol (55). DAAs may be administered concomitantly or may be delayed (especially in the 




 Mixed cryoglobulinemia is an immune-mediated process that becomes independent from the 
triggering virus. Rituximab is much more selective than conventional immunosuppressive 
treatments at interfering with the downstream processes following the disease trigger. 
 Data on DAAs efficacy in HCV-associated cryoglobulinemic vasculitis are disappointing 
possibly due to the inability of these drugs to suppress the immune-mediated process once it 
has been triggered. 
 Rituximab, able to deplete CD19 positive-B cells, known to be HCV reservoirs, could 
contribute to viral eradication making its combination with DAAs particularly attractive in 
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Fig. 1. Skin ulcers healing after Rituximab treatment. 
 
 
Fig 2. HCV RNA serum load as evaluated at 0, 3, 6, 9, 12 and 18 months and then yearly after Rituximab 
administration in our cohort of 31 patients with severe mixed cryoglobulinemic vasculitis (type II in 29 
cases and type III in 2) with diffuse membranoproliferative glomerulonephritis (16 cases), peripheral 







Fig. 3. Representative dot-plots of TReg (CD4+CD25+FOXP3+, top plots),  and B-cell (CD 20+, central 
plots) and activated T CD8+ cell (CD 20+, lower plots) as evaluated by flow cytometry. Samples from a 
responder patient analysed before and at 6 and 12 months after Rituximab administration. Upon 
detection of B cell depletion, a 9-fold increase in the circulating  Treg (CD4+CD25+FOXP3+) and a 7.5-
 14 
 











1.  Pascual M, Perrin L, Giostra E, Schifferli JA. Hepatitis C virus in patients with 
cryoglobulinemia type II. J Infect Dis . 1990; 162: 569–70.  
2.  Durand JM, Lefevre P, Harle JR, Boucrat J, Vitviski L, Soubeyrand J. Cutaneous vasculitis 
and cryoglobulinaemia type II associated with hepatitis C virus infection. Lancet. 1991; 
337: 499–500.  
3.  Casato M, Taliani G, Pucillo LP, Goffredo F, Laganà B, Bonomo L. Cryoglobulinaemia and 
hepatitis C virus. Lancet . 1991; 337: 1047–8.  
4.  Ferri C, Longombardo G, La Civita L, Bombardieri S, Greco F, Highfield P, Corbishley T. 
Hepatitis C virus, autoimmune liver disease and cryoglobulinaemic hepatitis. J Hepatol . 
1992; 16: 242–3.  
5.  Misiani R, Bellavita P, Fenili D, Borelli G, Marchesi D, Massazza M, Vendramin G, Comotti 
B, Tanzi E, Scudeller G. Hepatitis C virus infection in patients with essential mixed 
cryoglobulinemia. Ann Intern Med . 1992; 117: 573–7.  
6.  Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II 
cryoglobulinemia. N Engl J Med . 1992; 327: 1490–5.  
7. Roccatello D, Fornasieri A, Giachino O, Rossi D, Beltrame A, Banfi G, Confalonieri R, Tarantino 
A, Pasquali S, Amoroso A, Savoldi S, Colombo V, Manno C, et al. Multicenter study on 
hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis . 2007; 
49: 69–82.  
8.  Menegatti E, Davit A, Francica S, Berardi D, Rossi D, Baldovino S, Tovo PA, Sena LM, 
Roccatello D. Genetic factors associated with rheumatoid arthritis and systemic 
vasculitis: Evaluation of a panel of polymorphisms. Dis Markers. 2009; 27: 217–23.  
 16 
 
9.  Menegatti E, Messina M, Oddone V, Rubini E, Sciascia S, Naretto C, Baldovino S, Roccatello 
D. Immunogenetics of complement in mixed cryoglobulinaemia. Clin Exp Rheumatol. 
2016.  
10.  Caussin-Schwemling C, Schmitt C, Stoll-Keller F. Study of the infection of human blood 
derived monocyte/macrophages with hepatitis C virus in vitro. J Med Virol . 2001; 65: 
14–22.  
11.  Ito M, Murakami K, Suzuki T, Mochida K, Suzuki M, Ikebuchi K, Yamaguchi K, Mizuochi T. 
Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of 
chronic hepatitis C patients. Clin Immunol . 2010; 135: 459–65.  
12.  Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch 
recombination and hypermutation require activation-induced cytidine deaminase (AID), 
a potential RNA editing enzyme. Cell . 2000; 102: 553–63.  
13.  Roccatello D, Morsica G, Picciotto G, Cesano G, Ropolo R, Bernardi MT, Cacace G, Cavalli 
G, Sena LM, Lazzarin A, Piccoli G, Rifai A. Impaired hepatosplenic elimination of 
circulating cryoglobulins in patients with essential mixed cryoglobulinaemia and 
hepatitis C virus (HCV) infection. Clin Exp Immunol . 1997; 110: 9–14.  
14.  Roccatello D, Isidoro C, Mazzucco G, Mesiti A, Quattrocchio G, Amore A, Molino A, Coppo 
R, Sena LM, Piccoli G. Role of monocytes in cryoglobulinemia-associated nephritis. Kidney 
Int . 1993; 43: 1150–5.  
15.  Guo S, Wietecha TA, Hudkins KL, Kida Y, Spencer MW, Pichaiwong W, Kojima I, Duffield 
JS, Alpers CE. Macrophages are essential contributors to kidney injury in murine 
cryoglobulinemic membranoproliferative glomerulonephritis. Kidney Int . 2011; 80: 
946–58.  
16.  Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, 
 17 
 
Fanin R, Ferraccioli G. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. 
Blood . 2003; 101: 3827–34. d 
17.  De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased 
experience and perspectives. Dig Liver Dis . 2007; 39: 122–8.  
18.  Saadoun D, Rosenzwajg M, Landau D, Piette JC, Klatzmann D, Cacoub P. Restoration of 
peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. 
Blood . 2008; 111: 5334–41.  
19.  Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex 
with IgMκ mixed cryoglobulin and induce severe systemic reactions in patients with 
hepatitis C virus-induced vasculitis. Arthritis Rheum . 2009; 60: 3848–55.  
20.  Cavallo R, Roccatello D, Menegatti E, Naretto C, Napoli F, Baldovino S. Rituximab in 
cryoglobulinemic peripheral neuropathy. J Neurol . 2009; 256: 1076–82.  
21.  Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, Schoindre Y, Coppere 
B, Blanc F, Musset L, Piette J-C, Rosenzwajg M, Cacoub P. Rituximab plus Peg-
interferon- /ribavirin compared with Peg-interferon- /ribavirin in hepatitis C-related 
mixed cryoglobulinemia. Blood . 2010; 116: 326–34.  
22.  Terrier B, Saadoun D, Sène D, Sellam J, Pérard L, Coppéré B, Karras A, Blanc F, Buchler M, 
Plaisier E, Ghillani P, Rosenzwajg M, Cacoub P. Efficacy and tolerability of rituximab with 
or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related 
vasculitis: A long-term followup study of thirty-two patients. Arthritis Rheum . 2009; 60: 
2531–40.  
23.  Terrier B, Launay D, Kaplanski G, Hot  a, Larroche C, Cathébras P, Combe B, de 
Jaureguiberry JP, Meyer O, Schaeverbeke T, Somogyi A, Tricot L, Zénone T, et al. Safety 
and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French 
 18 
 
Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken) . 2010; 62: 1787–
95.  
24.  Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, Arena U, Giannini C, 
Monti M, Montalto P, Matucci-Cerinic M, Bosi A, Laffi G, et al. Safety and efficacy of 
rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe 
liver disease. Blood. 2010; 116: 335–42.  
25.  Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, Monti M, Petrarca A, Ranieri J, 
Razzolini G, Froio V, Laffi G, Zignego AL. Genetic determinants in hepatitis C virus-
associated mixed cryoglobulinemia: Role of polymorphic variants of BAFF promoter and 
Fcγ receptors. Arthritis Rheum . 2011; 63: 1446–51.  
26.  Visentini M, Ludovisi S, Petrarca A, Pulvirenti F, Zaramella M, Monti M, Conti V, Ranieri J, 
Colantuono S, Fognani E, Piluso A, Tinelli C, Zignego AL, et al. A phase II, single-arm 
multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia 
secondary to hepatitis C virus infection. Autoimmun Rev . Elsevier B.V.; 2011; 10: 714–9.  
27.  Stasi C, Triboli E, Arena U, Urraro T, Petrarca A, Gragnani L, Laffi G, Zignego AL. 
Assessment of liver stiffness in patients with HCV and mixed cryoglobulinemia 
undergoing rituximab treatment. J Transl Med . Journal of Translational Medicine; 2014; 
12: 21.  
28.  Visentini M, Tinelli C, Colantuono S, Monti M, Ludovisi S, Gragnani L, Mitrevski M, Ranieri 
J, Fognani E, Piluso A, Granata M, De Silvestri A, Scotti V, et al. Efficacy of low-dose 
rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial 
and systematic review. Autoimmun Rev . Elsevier B.V.; 2015; 14: 1–8.  
29.  Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, Tavoni A, Zignego ALL, 
De Vita S. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: 
 19 
 
Results of multicenter cohort study and review of the literature. Autoimmun Rev . 
Elsevier B.V.; 2011; 11: 48–55.  
30.  Roccatello D, Baldovino S, Rossi D, Giachino O, Mansouri M, Naretto C, Di Simone D, 
Francica S, Cavallo R, Alpa M, Napoli F, Sena LM. Rituximab as a therapeutic tool in severe 
mixed cryoglobulinemia. Clin Rev Allergy Immunol. 2008; 34: 111–7.  
31.  Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody 
treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. 
Blood . 2003; 101: 3818–26.  
32.  Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, Sansonno S, Russi S, 
Mariggio MA, Chironna M, Sansonno D. Pegylated interferon- , ribavirin, and rituximab 
combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term 
study. Blood . 2010; 116: 343–53.  
33.  Sneller MC, Hu Z, Langford C a. A randomized controlled trial of rituximab following 
failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. 
Arthritis Rheum . 2012; 64: 835–42.  
34.  De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, Campanini M, Naclerio C, 
Tavoni  a., Pietrogrande M, Ferri C, Mascia MT, Masolini P, et al. A randomized controlled 
trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis 
Rheum . 2012; 64: 843–53.  
35.  Roccatello D, Sciascia S, Baldovino S, Rossi D, Alpa M, Naretto C, Di Simone D, Menegatti 
E. Improved (4 plus 2) Rituximab protocol for severe cases of mixed cryoglobulinemia: a 
6-year observational study. Am J Nephrol. 2016; Am J Nephrol. 2016; 43: 251-60. 
36.   Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, 
Costanzo P, Giachino O, Mazzucco G, Sena LM. Long-term effects of anti-CD20 monoclonal 
 20 
 
antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant . 
2004; 19: 3054–61.  
37.     Yang CH, Qureshi AA, Churchill WH, Saavedra AP. Long-term plasmapheresis in 
conjunction with thalidomide and dexamethasone for the treatment of cutaneous ulcers 
and neovascular glaucoma in recalcitrant type I cryoglobulinemia. JAMA dermatology . 
2014; 150: 426–8.  
 
38.  Lee SS, Bain VG, Peltekian K, Krajden M, Yoshida EM, Deschenes M, Heathcote J, Bailey RJ, 
Simonyi S, Sherman M, CANADIAN PEGASYS STUDY GROUP. Treating chronic hepatitis C 
with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment 
Pharmacol Ther . 2006; 23: 397– 408.  
39.  McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee 
WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, et al. Peginterferon alfa-2b or 
alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med . 2009; 361: 580–
93.  
40.  Makara M, Sulyok M, Csacsovszki O, Sulyok Z V-NI. Successful treatment of HCV-
associated cryoglobulinemia with ombitasvir/paritaprevir/ritonavir, dasabuvir and 
ribavirin: A case report. J CLin Virol. 2015; 72: 66–8.  
41.  Sollima S, Milazzo L, Peri AM, Torre A, Antinori S, Galli M. Persistent mixed 
cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free 
antiviral therapy. Rheumatology (Oxford) . 2016; . doi: 10.1093/rheumatology/kew268. 
42.  Urraro T, Gragnani L, Piluso A, Fabbrizzi A, Monti M, Fognani E, Boldrini B, Ranieri J, 
Zignego AL. Combined treatment with antiviral therapy and rituximab in patients with 
mixed cryoglobulinemia: review of the literature and report of a case using direct 
 21 
 
antiviral agents-based antihepatitis C virus therapy. Case reports Immunol . 2015; 2015: 
816424.  
43.  Taraborelli M, Monari P, Cavazzana I, Gualdi G, Calzavara-Pinton P, Franceschini F. Severe 
skin involvement in type II cryoglobulinemia successfully treated with thalidomide. Joint 
Bone Spine . 2015; 82: 130–1.  
44.  Besada E, Vik A, Koldingsnes W, Nossent JC. Successful treatment with bortezomib in 
type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and 
literature review. Int J Hematol . 2013; 97: 800–3.. 
45.  Spizzo G, Mitterer M, Gunsilius E. Bortezomib for the treatment of refractory Type-1 
cryoglobulinaemia. Br J Haematol . 2010; 150: 235–7.  
46.  Cohen C, Mekinian A, Saidenberg-Kermanac’h N, Stirnemann J, Fenaux P, Gherardi R, Fain 
O. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Ann 
Rheum Dis . 2012; 71: 628–9. 
 47.     Sise ME, Bloom AK, Wisocky J, Lin M V, Gustafson JL, Lundquist AL, Steele D, Thiim M, 
Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT. Treatment of hepatitis C virus-
associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology . 
2016; 63: 408–17.  
48.   Cornella SL, Stine JG, Kelly V, Caldwell SH, Shah NL. Persistence of mixed cryoglobulinemia 
despite cure of hepatitis C with new oral antiviral therapy including direct-acting 
antiviral sofosbuvir: A case series. Postgrad Med . 2015; 127: 413–7.  
49.      Lauletta G, Russi S, Pavone F, Vacca A, Dammacco F. Direct-acting antiviral agents in the 
therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. 
Arthritis Res Ther. 2017 Apr 8;19(1): 74.  
 22 
 
50.     Bonacci M, Lens S, Mariño Z, Londoño MC, Rodriguez-Tajes S, Sánchez-Tapias JM, Ramos-
Casals M, Hernández-Rodríguez J, Forns X. Long-Term Outcomes of Patients With HCV-
Associated Cryoglobulinemic Vasculitis After Virologic Cure. Gastroenterology. 2018; 
155(2): 311-315. 
*51.     Emery JS, Kuczynski M, La D, Almarzooqi S, Kowgier M, Shah H, Wong D, Janssen HLA, 
Feld JJ. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed 
Cryoglobulinemia. Am J Gastroenterol. 2017; 112(8): 1298-1308. 
* 
**52.    Cacoub P, Si Ahmed SN, Ferfar Y, Pol S, Thabut D, Hezode C, Alric L, Comarmond C, Ragab 
G, Quartuccio L, Hegazy M, Poynard T, Resche Rigon M, Saadoun D. Long-term Efficacy of 
Interferon-Free Antiviral Treatment Regimens in Patients With Hepatitis C Virus-
Associated Cryoglobulinemia Vasculitis. Clin Gastroenterol Hepatol. 2019 Feb;17(3): 518-
526.  
** 
53.  Del Padre M, Todi L, Mitrevski M, Marrapodi R, Colantuono S, Fiorilli M, Casato M, Visentini 
M. Reversion of anergy signatures in clonal CD21 low B cells of mixed cryoglobulinemia 
after clearance of HCV viremia. Blood. 2017; 130(1): 35-38. 
*54. Ramos-Casals, M. et al.Evidence-based recommendations on the management of 
extrahepatic manifestations of chronic hepatitis C virus infection. J. Hepatol. 66, 1282–
1299 (2017). 
** 
**55.   Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, Zignego 
AL, Ferri C. Cryoglobulinemia. Nat Rev Dis Primers. 2018 Aug 2; 4(1): 11. doi: 
 23 
 
10.1038/s41572-018-0009-4 
**---- 
